No abstract available
Keywords:
AZD1152; Aurora B kinase; barasertib; diffuse large B-cell lymphoma; lymphoid malignancies.
Publication types
-
Clinical Trial, Phase II
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Female
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / pathology*
-
Male
-
Middle Aged
-
Organophosphates / administration & dosage
-
Organophosphates / adverse effects
-
Organophosphates / therapeutic use*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use*
-
Recurrence
-
Treatment Outcome
Substances
-
2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
-
Antineoplastic Agents
-
Organophosphates
-
Protein Kinase Inhibitors
-
Quinazolines
Associated data
-
ClinicalTrials.gov/NCT01354392